SULT2A1

Across TCGA pan-cancer cohorts, SULT2A1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SULT2A1’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where SULT2A1 RNA is repressed in tumor relative to normal tissue. In most cancer types SULT2A1 is over-expressed in tumor, although a few such as STAD and CHOL show the opposite, repressed pattern.

STAD, CHOL, and LIHC are the cancer types where SULT2A1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SULT2A1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Male	IV	−3.085	.007	7	view →
CHOL	Female	All	−9.170	<.001	5	view →
LIHC	All	All	−1.498	<.001	5	view →
HNSC	Male	III,IV	+0.063	.031	4	view →
PRAD	All	All	−0.685	.001	2	view →
PAAD	All	All	−0.035	.025	2	view →
ESCA	All	All	−2.365	.016	1	view →
KIRC	Male	All	+0.008	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SULT2A1–STAD

Open the STAD breakdown →